Alps Advisors Inc. Has $258000 Stake in Aduro BioTech Inc (NASDAQ:ADRO)

Alps Advisors Inc. decreased its stake in shares of Aduro BioTech Inc (NASDAQ:ADRO) by 12.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 167,524 shares of the biotechnology company’s stock after selling 24,267 shares during the period. Alps Advisors Inc. owned about 0.21% of Aduro BioTech worth $258,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of ADRO. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Aduro BioTech by 33.7% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 44,895 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 11,318 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Aduro BioTech by 196.5% during the second quarter. JPMorgan Chase & Co. now owns 1,414,065 shares of the biotechnology company’s stock valued at $2,474,000 after acquiring an additional 937,166 shares during the period. Wells Fargo & Company MN increased its stake in shares of Aduro BioTech by 62.9% during the second quarter. Wells Fargo & Company MN now owns 52,531 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 20,286 shares during the period. Swiss National Bank increased its stake in shares of Aduro BioTech by 21.4% during the second quarter. Swiss National Bank now owns 89,000 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 15,700 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its stake in shares of Aduro BioTech by 32.0% during the second quarter. Candriam Luxembourg S.C.A. now owns 239,000 shares of the biotechnology company’s stock valued at $366,000 after acquiring an additional 58,000 shares during the period. 41.69% of the stock is currently owned by institutional investors and hedge funds.

Aduro BioTech stock traded down $0.01 during midday trading on Friday, reaching $1.05. The stock had a trading volume of 700,600 shares, compared to its average volume of 363,038. The firm’s fifty day simple moving average is $1.27 and its two-hundred day simple moving average is $2.38. Aduro BioTech Inc has a twelve month low of $1.04 and a twelve month high of $7.64. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.45 and a quick ratio of 8.45. The firm has a market cap of $87.35 million, a price-to-earnings ratio of -0.91 and a beta of 1.48.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.05). The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.56 million. Aduro BioTech had a negative net margin of 624.51% and a negative return on equity of 68.69%. As a group, sell-side analysts predict that Aduro BioTech Inc will post -0.95 EPS for the current fiscal year.

In related news, CEO Stephen T. Isaacs sold 31,098 shares of Aduro BioTech stock in a transaction on Friday, September 13th. The shares were sold at an average price of $1.31, for a total value of $40,738.38. Following the completion of the sale, the chief executive officer now owns 295,926 shares of the company’s stock, valued at approximately $387,663.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 52,185 shares of company stock valued at $68,362 in the last three months. Company insiders own 5.20% of the company’s stock.

A number of research analysts recently commented on ADRO shares. ValuEngine upgraded shares of Aduro BioTech from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Cowen restated a “buy” rating on shares of Aduro BioTech in a research report on Friday, August 2nd. Oppenheimer lowered shares of Aduro BioTech from an “outperform” rating to a “market perform” rating in a research report on Monday, June 3rd. Finally, CIBC restated a “market perform” rating on shares of Aduro BioTech in a research report on Monday, June 3rd. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $8.01.

Aduro BioTech Company Profile

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.